Pursuant to section 20 of the Medicines Act 1981, the Minister of Health hereby consents to the distribution in New Zealand of the new medicines which were referred to the Minister of Health under the provisions of section 24(5) of the Act and are set out in the Schedule hereto:
Schedule
Product: Active Ingredient: Dosage Form: New Zealand Sponsor: Manufacturer:
|
Apo-Diltiazem CD Diltiazem hydrochloride 120.12mg Modified release capsule Apotex NZ Limited Apotex Inc, Ontario, Canada
|
Product: Active Ingredient: Dosage Form: New Zealand Sponsor: Manufacturer:
|
Apo-Diltiazem CD Diltiazem hydrochloride 180.1mg Modified release capsule Apotex NZ Limited Apotex Inc, Ontario, Canada
|
Product: Active Ingredient: Dosage Form: New Zealand Sponsor: Manufacturer:
|
Apo-Diltiazem CD Diltiazem hydrochloride 240.1mg Modified release capsule Apotex NZ Limited Apotex Inc, Ontario, Canada
|
Product: Active Ingredient: Dosage Form: New Zealand Sponsor: Manufacturer:
|
Apo-Diltiazem CD Diltiazem hydrochloride 300mg Modified release capsule Apotex NZ Limited Apotex Inc, Ontario, Canada
|
Product: Active Ingredient: Dosage Form: New Zealand Sponsor: Manufacturer:
|
Spiriva Respimat Tiotropium bromide monohydrate 3.125mcg equivalent to Tiotropium 2.5mcg/dose Solution for inhalation Boehringer Ingelheim (NZ) Limited Boehringer Ingelheim Pharma GmbH & Co KG, Ingelheim am Rhein, Germany
|
Dated this 23rd day of April 2015.
SARAH READER, Acting Group Manager, Medsafe, Ministry of Health (pursuant to delegation given by the Minister of Health on 11 September 2013).